Skip to main content

#151345

Anti-Leu2 [C8/144B] mAb

Cat. #151345

Anti-Leu2 [C8/144B] mAb

Cat. #: 151345

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Leu2 (CD8)

Class: Monoclonal

Application: IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jacqueline Cordell

Institute: University of Oxford

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Leu2 [C8/144B] mAb
  • Alternate name: CD8a Molecule; T-Lymphocyte Differentiation Antigen T8/Leu-2; CD8 Antigen; Alpha Polypeptide (P32); MAL; T-Cell Surface Glycoprotein CD8 Alpha Chain; Leu2 T-Lymphocyte Antigen; OKT8 T-Cell Antigen; T-Cell Antigen Leu2; T8 T-Cell Antigen; CD8a Antigen; Leu2; P32
  • Cancer: Blood cancer
  • Cancers detailed: Leukemia;Lymphoma
  • Research fields: Immunology;Stem cell biology
  • Clone: C8/144B
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Application: IHC ; IF ; IP ; WB
  • Description: C8/144B can be used to detect these cells in tissue sections and also their neoplastic counterparts.
  • Immunogen: Synthetic peptide (the 13 C-terminal residues of the cytoplasmic domain of human CD8a)
  • Isotype: IgG1
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Leu2 (CD8)
  • Target background: CD8 is a T cell co-receptor that recognises, together with the T cell receptor, MHC class I molecules. CD8 is present on human suppressor/cytotoxic T cells which make up 30% of circulating T cells.

Applications

  • Application: IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Dry ice

References

  • van Gool et al. 2015. Clin Cancer Res. 21(14):3347-55. PMID: 25878334.
  • POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.
  • Harlin et al. 2009. Cancer Res. 69(7):3077-85. PMID: 19293190.
  • Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
  • Sato et al. 2005. Proc Natl Acad Sci U S A. 102(51):18538-43. PMID: 16344461.
  • Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
  • Mason et al. 1992. J Clin Pathol. 45(12):1084-8. PMID: 1479035.
  • Immunohistological detection of human cytotoxic/suppressor T cells using antibodies to a CD8 peptide sequence.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.